Amprenavir
- Generic Name
- Amprenavir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H35N3O6S
- CAS Number
- 161814-49-9
- Unique Ingredient Identifier
- 5S0W860XNR
- Background
Amprenavir is a protease inhibitor used to treat HIV infection.
- Indication
用于高效抗逆转录病毒疗法（HAART）的组成药物。
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00002193
- Locations
- 🇺🇸
Children's Diagnostic Treatment Ctr, Fort Lauderdale, Florida, United States
🇺🇸Saint Jude Children's Hosp / Dept of Infect Diseases, Memphis, Tennessee, United States
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 30
- Registration Number
- NCT00002233
- Locations
- 🇺🇸
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States
🇺🇸Miriam Hosp / Family Healthcare Ctr at SSTAR, Providence, Rhode Island, United States
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-06-07
- Target Recruit Count
- 900
- Registration Number
- NCT00000919
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00002239
- Locations
- 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States
A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002216
- Locations
- 🇺🇸
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 42
- Registration Number
- NCT00006152
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸Univ of Texas Galveston, Galveston, Texas, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-05-15
- Target Recruit Count
- 25
- Registration Number
- NCT00006617
- Locations
- 🇺🇸
Aaron Diamond AIDS Res Ctr, New York, New York, United States
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 100
- Registration Number
- NCT00002423
- Locations
- 🇺🇸
IDC Research Initiative, Altamonte Springs, Florida, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Kansas City AIDS Research Consortium, Kansas City, Missouri, United States
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
- Conditions
- Locations
- 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.